Journal article
A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours
Abstract
BACKGROUND: This phase I study was performed to evaluate the safety, tolerability, and efficacy of the oral matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced solid tumours, and to identify the maximum tolerated dose and dose for use in subsequent studies.
PATIENTS AND METHODS: BAY 12-9566 was administered to 29 patients at doses ranging from 100 mg o.d. to 1600 mg (given either 400 mg q.i.d. or 800 mg b.i.d.). Blood …
Authors
Hirte H; Goel R; Major P; Seymour L; Huan S; Stewart D; Yau J; Arnold A; Holohan S; Waterfield B
Journal
Annals of Oncology, Vol. 11, No. 12, pp. 1579–1584
Publisher
Elsevier
Publication Date
December 2000
DOI
10.1023/a:1008347630465
ISSN
0923-7534